

Flexible, Fast and Future Production Processes

Mark White DPS Engineering 9th March, 2016



Small Molecule - "The Silent Majority"

Small molecules:

- Account for ~82% of new drug applications (2014)
- ~60% of new molecular entities (2014)
- Highly potent API's is a particularly strong sector



Current Industry Trends









Fewer 'Blockbuster' drugs in Pipeline

- Focus on Speciality Pharma / Patient Needs e.g. Oncology
- Smaller Volumes / Higher Potency Drugs ('Nichebusters')

Need to get to Market Sooner

- Reduced Development Time
- Faster Production of Kilo Quantities

Rebalancing of Manufacturing Assets

- Large Scale API hardest hit
- Evolution & Repurposing of Manufacturing Sites

Lab Scale to Batch Scale

- Scale Up Efficiency
- Reduced Turnaround Times



Small Scale Project Drivers

Small Volume "Niche" Drug Products

Fast & Flexible Production of (Early Phase) Pharma Materials

- Sustainable Production Technology
- Reduced Capital Investment for NPI (New Product Introductions)
- Bulk API Plant Operating Efficiencies



Small Scale Production Facility Production **Existing Reactor** Cap Identified ovisia a Bulk API Facility **Suites** Capacities not suitable for low volumes Manufacturing & Isolation Product Capability • introductions slow & costly "Fast-Flexible concerned" Options Within Existing Make best use European Initiative of existing real estate Future proof Investment **Reuse existing** utility services



Capability Gap

Legacy manufacturing sites

- Typical production reactor volumes
 6000 8000L
- Old style product introduction reactor volumes 1000 – 2500L
- More potent drugs significant infrastructural gap exists





Small Scale Manufacturing Suites

New facilities

- New capacity requirements reactor volumes 80 to 300L
- Close containment gap facility design and containment approach
- Facilities infrastructure
- GMP considerations



Small Scale Manufacturing Suites – Case Study 1



Small Scale Manufacturing Suites – Case Study 2





Flexibility Modules

- Trickle bed hydrogenation
- Plug flow reactors (static mixers)
- Continuous crystallization (CSTR)
- Continuous liquid-liquid extraction
- Vapour-liquid separation
- Chromatography purification technology
- Continuous filter drying





Learn from F3 concept

- Public/private sector initiative launched in 2009
- Develop modularised process operations
- Design and utilisation of a common large scale 'back bone' facility
- GMP considerations





Learn from F3 concept








F3

creating the future of production









Standardized interface between equipment and back bone

Utilities provided by the standardized backbone:

- Electricity, control command, etc.
- Service fluid, etc.






Implement concept

- Backbone amended to suit available real estate and infrastructure
- Allow for interaction with modularised units
- Key is utility provision, supply and receiver vessel provision




Backbone utilities






F3 Implementation





F3 Implementation





F3 Implementation





Early Project Challenges



- Design to a budget or budget to a design
- Early approval vs. contingency risks

- Value Engineering

 a team based exercise
- Client changes

- Fast track;
 18 months to 12
 12 months to 8
- Allow design process to develop



Fast Track Design



Design Development Highly Interactive



Early Piping Design



Change Management

- Significant P&ID and design document reviews
- Extensive modelling reviews

- Develop isometrics from HAZOP issue PIDs
- Client buys into element of risk
- Depending on delivery , MTO for lined pipe issued and procured at intervals

- Expedited approval cycles
- Traceability



Design for everything




Candy shop

- Multiple 'process fit' evaluations
- Provision for process modules per F3 concept
- Better to omit a unit operation than reduce functionality
- Re-engineering and rolling with the punches



Design for everything





Small Scale Scope



Core Equipment

- Reactors/ crystallisers (varying sizes and MOC)
- Hydrogenator
- Isolation device (Centrifuge, Filter Drier)




Ancillary Equipment

- Head Tanks
- Receivers
- Solvent booths




Hydrogenation






Small Scale





Diversity




Design Range
✓ Agree pressure range
Agree temperature range
Develop HAC rating for facility



Intermediate Scale Section



Interconnectivity



Use of manifolds and hoses



Use of mobile and movable equipment

Plug and Play fixed / mobile equipment and skids



Interconnectivity



Manumatic

Automation

Interlocking

Automated standard

operations




Intermediate Scale Plan 1SR FLR





Containment




Scalable technology to OEB4 / OEB5





Dispensary





Engage with All Stakeholders from Outset

- Include in Early Reviews & 3D Interactions
- Solicit Opinions

Optimise trade-off between 'Best' Layout v. Minimum Hold-Up

- Vertical Stack-up Preferred
- Never Base Design on Large Scale API Equipment



Value Engineer From the Outset

- Agree Scope Early Late Design Changes are Major Impacts
- ⁻ Track All Changes

Never Underestimate Piping or Instrumentation Design

- Maintenance and Operator Access Must be Incorporated
- Only Vessels are Small Scale!



Current Industry Trends (reprise)









Fewer 'Blockbuster' drugs in Pipeline

- Focus on Speciality Pharma / Patient Needs e.g. Oncology
- Smaller Volumes / Higher Potency Drugs ('Nichebusters')

Need to get to Market Sooner

- Reduced Development Time
- Faster Production of Kilo Quantities

Rebalancing of Manufacturing Assets

- Large Scale API hardest hit
- Evolution & Repurposing of Manufacturing Sites

Lab Scale to Batch Scale

- Scale Up Efficiency
- Reduced Turnaround Times



Flexible Approach

Project Success

Integrated Team

Mark White Group Engineering Lead mark.white@dpsgroupglobal.com



